Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1966 1
1972 1
1977 1
1978 2
1981 1
1983 1
1986 1
1987 4
1988 1
1989 2
1991 4
1992 6
1994 1
1995 2
1996 2
1997 3
1999 5
2000 2
2001 10
2002 5
2003 4
2004 9
2005 5
2006 10
2007 10
2008 12
2009 8
2010 17
2011 20
2012 16
2013 18
2014 15
2015 9
2016 19
2017 9
2018 17
2019 20
2020 17
2021 28
2022 28
2023 14
2024 17
2025 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

349 results

Results by year

Filters applied: . Clear all
Page 1
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O'Shaughnessy J. Hortobagyi GN, et al. Among authors: alba e. N Engl J Med. 2016 Nov 3;375(18):1738-1748. doi: 10.1056/NEJMoa1609709. Epub 2016 Oct 7. N Engl J Med. 2016. PMID: 27717303 Free article. Clinical Trial.
Adjuvant trastuzumab in HER2-positive breast cancer.
Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group. Slamon D, et al. N Engl J Med. 2011 Oct 6;365(14):1273-83. doi: 10.1056/NEJMoa0910383. N Engl J Med. 2011. PMID: 21991949 Free PMC article. Clinical Trial.
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Lee ES, Pierga JY, Bermejo B, Ramos-Vazquez M, Jung KH, Ferrero JM, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Tripathy D, Pusztai L, Hortobagyi GN. Kalinsky K, et al. Among authors: alba e. N Engl J Med. 2021 Dec 16;385(25):2336-2347. doi: 10.1056/NEJMoa2108873. Epub 2021 Dec 1. N Engl J Med. 2021. PMID: 34914339 Free PMC article. Clinical Trial.
Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group.
Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Boughey J, Curigliano G, Dixon JM, Esserman L, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Symmans WF; Residual Disease Characterization Working Group of the Breast International Group-North American Breast Cancer Group Collaboration. Provenzano E, et al. Mod Pathol. 2015 Sep;28(9):1185-201. doi: 10.1038/modpathol.2015.74. Epub 2015 Jul 24. Mod Pathol. 2015. PMID: 26205180 Free article.
High Mechanical Conditioning by Tumor Extracellular Matrix Stiffness Is a Predictive Biomarker for Antifibrotic Therapy in HER2-Negative Breast Cancer.
Quintela-Fandino M, Bermejo B, Zamora E, Moreno F, García-Saenz JÁ, Pernas S, Martínez-Jañez N, Jiménez D, Adrover E, de Andrés R, Mourón S, Bueno MJ, Manso L, Viñas G, Alba E, Llombart-Cussac A, Cortés J, Tebar C, Roe DJ, Grant A, Watson A, Colomer R, Mouneimne G. Quintela-Fandino M, et al. Among authors: alba e. Clin Cancer Res. 2024 Nov 15;30(22):5094-5104. doi: 10.1158/1078-0432.CCR-24-1518. Clin Cancer Res. 2024. PMID: 39283720 Clinical Trial.
Ocular side effects of checkpoint inhibitors.
Alba-Linero C, Alba E. Alba-Linero C, et al. Among authors: alba e. Surv Ophthalmol. 2021 Nov-Dec;66(6):951-959. doi: 10.1016/j.survophthal.2021.01.001. Epub 2021 Jan 10. Surv Ophthalmol. 2021. PMID: 33440195 Review.
Gestational breast cancer: distinctive molecular and clinico-epidemiological features.
de la Haba-Rodríguez JR, Mínguez P, Rojo F, Martín M, Alba E, Servitja S, Prat A, Pérez-Fidalgo JA, Gavilá J, Morales C, Rodriguez-Lescure A, Herrero C, Peña-Enriquez R, Herranz J, Hernando C, Hernández-Blanquisett A, Guil-Luna S, Martinez MT, Blanch S, Caballero R, Martín N, Pollán M, Guerrero-Zotano A, Bermejo B. de la Haba-Rodríguez JR, et al. Among authors: alba e. J Mammary Gland Biol Neoplasia. 2024 Nov 8;29(1):18. doi: 10.1007/s10911-024-09571-3. J Mammary Gland Biol Neoplasia. 2024. PMID: 39514034 Free PMC article.
Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy.
Pernas S, Sanfeliu E, Villacampa G, Salvador J, Perelló A, González X, Jiménez B, Merino M, Palacios P, Pascual T, Alba E, Villanueva L, Chillara S, Ferrero-Cafiero JM, Galvan P, Prat A, Ciruelos E. Pernas S, et al. Among authors: alba e. NPJ Breast Cancer. 2024 Nov 26;10(1):101. doi: 10.1038/s41523-024-00710-x. NPJ Breast Cancer. 2024. PMID: 39592624 Free PMC article.
349 results